丰原药业
(000153)
| 流通市值：26.11亿 | | | 总市值：27.16亿 |
| 流通股本：3.19亿 | | | 总股本：3.32亿 |
| 报告期 | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 1,120,669,012.93 | 4,275,436,713.72 | 3,224,068,934.15 | 2,285,417,858.93 |
| 营业收入 | 1,120,669,012.93 | 4,275,436,713.72 | 3,224,068,934.15 | 2,285,417,858.93 |
| 二、营业总成本 | 1,058,729,460.12 | 4,098,576,045.54 | 3,054,625,491.37 | 2,156,020,286.08 |
| 营业成本 | 832,638,871.03 | 3,176,289,092.04 | 2,376,539,605.19 | 1,666,226,185.61 |
| 税金及附加 | 9,186,753.28 | 37,578,507.96 | 27,251,123.62 | 19,115,982.01 |
| 销售费用 | 159,552,828.87 | 584,288,566.79 | 453,203,772.32 | 333,900,217.1 |
| 管理费用 | 37,790,162.18 | 197,610,576.03 | 121,620,386.8 | 80,708,002.25 |
| 研发费用 | 12,983,646.7 | 77,023,417.77 | 55,452,321.19 | 41,387,908.33 |
| 财务费用 | 6,577,198.06 | 25,785,884.95 | 20,558,282.25 | 14,681,990.78 |
| 其中:利息费用 | 6,928,471.53 | 33,894,396.79 | 25,553,676.89 | 17,656,678.18 |
| 其中:利息收入 | 631,800.04 | 8,710,670.66 | 5,430,244.35 | 3,111,167.6 |
| 加:公允价值变动收益 | -10,444,151.2 | -6,920,724.85 | -14,371,030.19 | -1,596,034.86 |
| 加:投资收益 | - | 5,342,262.43 | 5,221,805.57 | 14,430.32 |
| 资产处置收益 | - | 4,381,091.55 | 4,419,177.75 | 4,388,110.41 |
| 资产减值损失(新) | -1,341,208.31 | -8,335,909.67 | -3,730,375.24 | -3,365,069.35 |
| 信用减值损失(新) | -2,339,521.95 | 2,492,206.6 | 4,501,853.61 | -1,557,718.92 |
| 其他收益 | 18,765,531.63 | 39,433,999.7 | 23,433,964.66 | 15,618,034.9 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | 66,580,202.98 | 213,253,593.94 | 188,918,838.94 | 142,899,325.35 |
| 加:营业外收入 | 380,251.91 | 3,143,775.1 | 1,567,918.81 | 1,081,734.15 |
| 减:营业外支出 | 176,869.56 | 1,504,805.95 | 482,244.01 | 440,178.12 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | 66,783,585.33 | 214,892,563.09 | 190,004,513.74 | 143,540,881.38 |
| 减:所得税费用 | 20,420,044.17 | 57,595,861.3 | 48,673,780.86 | 41,255,996.73 |
| 六、净利润 | 46,363,541.16 | 157,296,701.79 | 141,330,732.88 | 102,284,884.65 |
| 持续经营净利润 | 46,363,541.16 | 157,296,701.79 | 141,330,732.88 | 102,284,884.65 |
| 归属于母公司股东的净利润 | 47,010,852.21 | 159,285,567.9 | 142,464,110.4 | 103,015,799.31 |
| 少数股东损益 | -647,311.05 | -1,988,866.11 | -1,133,377.52 | -730,914.66 |
| (一)基本每股收益 | 0.14 | 0.48 | 0.43 | 0.31 |
| (二)稀释每股收益 | 0.14 | 0.48 | 0.43 | 0.31 |
| 八、其他综合收益 | -92,681.15 | -1,846,777.03 | -724,453.83 | 2,405,195.31 |
| 归属于母公司股东的其他综合收益 | -174,632.28 | -2,077,877.7 | -896,561.1 | 2,268,733.66 |
| 九、综合收益总额 | 46,270,860.01 | 155,449,924.76 | 140,606,279.05 | 104,690,079.96 |
| 归属于母公司股东的综合收益总额 | 46,836,219.93 | 157,207,690.2 | 141,567,549.3 | 105,284,532.97 |
| 归属于少数股东的综合收益总额 | -565,359.92 | -1,757,765.44 | -961,270.25 | -594,453.01 |
| 公告日期 | 2024-04-26 | 2024-04-26 | 2023-10-27 | 2023-08-25 |
| 审计意见(境内) | | 标准无保留意见 | | |